The results demonstrated that SLFN5, SLFN11, SLFN12, SLFN12L, and SLFN13 expression in tumor tissues was significantly higher than that in normal tissues in paired, and unpaired tests, implying that they may play a role in promoting tumor progression in GC. The gene discussed is SLFN5; the disease is gastric cancer.